This is a sponsored article brought to you by PNY Technologies. In today’s data-driven world, data scientists face mounting ...

Clinical trial datasets are becoming increasingly complex, yet the format of their dissemination remains largely static.1 ...

A new research study showcases compelling evidence for AI-based mental health apps. Limitations exist. An AI Insider scoop.

A session focusing on chemometrics for food quality control and authentication will take place on March 25, 2026, from 15:00 ...

A session exploring the latest analytical and computational strategies in metabolomics/lipidomics is scheduled at analytica ...

Andrej Karpathy’s AI exposure study reveals risks to white-collar jobs, sparking debate before deletion of viral analysis ...

Château Puybarbe, an organic wine estate in Bordeaux owned and operated by Finnish winemakers Riku Väänänen and ...

C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation (R), highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset ...

New strategic resource examines how artificial intelligence is reshaping executive decision-making, governance, and ...

CDNS expands NVDA tie-up to power agentic AI, boosting design speed, efficiency and enabling next-gen chip, system and even drug discovery innovation.

A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...